KLF15 Agonist in Kidney Disease

JASN encourages investigators to submit their basic science original research to the journal. Editor-in-Chief Rajnish Mehrotra and Deputy Editors Alessia Fornoni and David H. Ellison discuss the types of basic research that JASN publishes.

Novel therapies for IgA nephropathy are discussed in this ASN Kidney Translation podcast episode, including efficacy and safety of ravulizumab, selective endothelin receptor antagonist SC0062, and long-term results from a study of atacicept as treatment.

Drs. Ivana Kuo and Karla M. Márquez-Nogueras discuss the results of their study, "Cardiac Localized Polycystin-2 in the Natriuretic Peptide Signaling Pathway and Hypertension," with JASN Deputy Editor David H. Ellison.

The inaugural ASN Kidney Health Guidance on the Management of Obesity in Persons Living with Kidney Diseases examines psychosocial considerations, lifestyle modifications, pharmacologic options, and metabolic/bariatric surgery.

Drs. Sandeep K. Mallipattu and Bhaskar Das discuss the findings from their study, "A Small Molecule Agonist of Krüppel-Like Factor 15 in Proteinuric Kidney Disease," with JASN Deputy Editor Alessia Fornoni.

Dr. Lilach O. Lerman discusses the results from her study, "Renovascular Disease and Mitochondrial Dysfunction in Human Mesenchymal Stem Cells," with JASN Deputy Editor Alessia Fornoni.

Issues of gender equity in nephrology are covered in an episode of ASN Kidney Translation: An ASN Journals' Podcast, including equal access to mentorship and research opportunities, fellowship programs' parental leave policies, and representation in RCTs.

Drs. Alicia A. McDonough and Aurelie Edwards discuss the findings from their study, "Potassium-Alkali–Enriched Diet, Hypertension, and Proteinuria following Uninephrectomy," with JASN Deputy Editor David H. Ellison.

JASN encourages investigators to submit their late-breaking clinical trial manuscripts for rapid consideration and peer review and, if accepted, online publication in JASN concurrent with Kidney Week.

Dr. Hiddo J.L. Heerspink discusses the findings from his study, "Effect of Avenciguat on Albuminuria in Patients with CKD: Two Randomized Placebo-Controlled Trials" with JASN Editor-in-Chief Rajnish Mehrotra.